Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies

被引：104

作者：

Salarinia, Reza ^{[1
,2
]}

Sahebkar, Amirhossein ^{[3
]}

Peyvandi, Mostafa ^{[4
,5
]}

Mirzaei, Hamid Reza ^{[6
]}

Jaafari, Mahmoud Reza ^{[7
]}

Riahi, Maryam Matbou ^{[1
]}

Ebrahimnejad, Hamed ^{[8
]}

Nahand, Javid Sadri ^{[9
]}

Hadjati, Jamshid ^{[6
]}

Asrami, Mobina Ostadi ^{[10
]}

Fadaei, Sara ^{[11
]}

Salehi, Rasoul ^{[12
]}

Mirzaei, Hamed ^{[1
]}

机构：

[1] Mashhad Univ Med Sci, Sch Med, Dept Med Biotechnol, Mashhad, Iran

[2] North Khorasan Univ Med Sci, Sch Med, Dept Med Biotechnol, Bojnourd, Iran

[3] Mashhad Univ Med Sci, Biotechnol Res Ctr, Mashhad, Iran

[4] Mashhad Univ Med Sci, Sch Med, Dept Anatom Sci, Mashhad, Iran

[5] Birjand Univ Med Sci, Sch Med, Dept Anatom Sci, Birjand, Iran

[6] Univ Tehran Med Sci, Sch Med, Dept Immunol, Tehran, Iran

[7] Mashhad Univ Med Sci, Sch Pharm, Nanotechnol Res Ctr, Mashhad, Iran

[8] Mashhad Univ Med Sci, Sch Dent, Maxillofacial Dis Res Ctr, Dept Oral & Maxillofacial Radiol, Mashhad, Iran

[9] Mashhad Univ Med Sci, Fac Med, Dept Microbiol & Virol, Mashhad, Iran

[10] Islamic Azad Univ Tonekabon, Dept Cellular & Mol Biotechnol, Mazandaran, Iran

[11] Kashan Univ Med Sci, Sch Med, Student Res Comm, Kashan, Iran

[12] Isfahan Univ Med Sci, Sch Med, Dept Med Genet, Esfahan, Iran

来源：

CURRENT CANCER DRUG TARGETS | 2016年 / 16卷 / 09期

关键词：

Cancer epigenetics; DNA methyltransferase inhibitor; Epi-drugs; Epi-miRs; Histone deacetylase inhibitor; HISTONE DEACETYLASE INHIBITOR; CPG ISLAND HYPERMETHYLATION; HUMAN COLORECTAL-CANCER; TUMOR-SUPPRESSOR GENES; CELL-CYCLE KINASES; PHASE-II TRIAL; DNA METHYLATION; EPIGENETIC REGULATION; PROSTATE-CANCER; DOWN-REGULATION;

D O I：

10.2174/1568009616666151207110143

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Epigenetic modifications determine phenotypic characteristics in a reversible, stable and genotype-independent manner. Epigenetic modifications mainly encompass CpG island methylation and histone modifications, both being important in the pathogenesis of malignancies. The reversibility of epigenetic phenomenon provides a suitable therapeutic option that is reactivation of epigenetically silenced tumor-suppressor genes. Inhibition of DNA methyltransferase, histone deacetylase and Aurora B kinase, individually or collectively, could feasibly prevent or reverse the impact of epigenetic silencing. MicroRNAs [miRNAs] are an important layer of epigenetic controlling of gene expression, and serve as diagnostic and prognostic biomarkers as well as treatment targets for several types of cancer. miRNAs are involved inepigenetically silencing or activation of genes, tumor-suppressor genes and oncogenes, and their modulation opens new horizons for designing novel cancer therapeutic agents.

引用

页码：773 / 788

页数：16

共 245 条

[1] Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells [J].

Abbosh, Phillip H. ;

Montgomery, John S. ;

Starkey, Jason A. ;

Novotny, Milos ;

Zuhowski, Eleanor G. ;

Egorin, Merrill J. ;

Moseman, Annie P. ;

Golas, Adam ;

Brannon, Kate M. ;

Balch, Curtis ;

Huang, Tim H. M. ;

Nephew, Kenneth P. .

CANCER RESEARCH, 2006, 66 (11) :5582-5591

[2] Discovery of GSK1070916, a Potent and Selective Inhibitor of Aurora B/C Kinase [J].

Adams, Nicholas D. ;

Adams, Jerry L. ;

Burgess, Joelle L. ;

Chaudhari, Amita M. ;

Copeland, Robert A. ;

Donatelli, Carla A. ;

Drewry, David H. ;

Fisher, Kelly E. ;

Hamajima, Toshihiro ;

Hardwicke, Mary Ann ;

Huffman, William F. ;

Koretke-Brown, Kristin K. ;

Lai, Zhihong V. ;

McDonald, Octerloney B. ;

Nakamura, Hiroko ;

Newlander, Ken A. ;

Oleykowski, Catherine A. ;

Parrish, Cynthia A. ;

Patrick, Denis R. ;

Plant, Ramona ;

Sarpong, Martha A. ;

Sasaki, Kosuke ;

Schmidt, Stanley J. ;

Silva, Domingos J. ;

Sutton, David ;

Tang, Jun ;

Thompson, Christine S. ;

Tummino, Peter J. ;

Wang, Jamin C. ;

Xiang, Hong ;

Yang, Jingsong ;

Dhanak, Dashyant .

JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (10) :3973-4001

[3] ACETYLATION + METHYLATION OF HISTONES + THEIR POSSIBLE ROLE IN REGULATION OF RNA SYNTHESIS [J].

ALLFREY, VG ;

FAULKNER, R ;

MIRSKY, AE .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1964, 51 (05) :786-+

[4] Regulation of placenta growth factor by microRNA-125b in hepatocellular cancer [J].

Alpini, Gianfranco ;

Glaser, Shannon S. ;

Zhang, Jing-Ping ;

Francis, Heather ;

Han, Yuyan ;

Gong, Jiao ;

Stokes, Allison ;

Francis, Taylor ;

Hughart, Nathan ;

Hubble, Levi ;

Zhuang, Shi-Mei ;

Meng, Fanyin .

JOURNAL OF HEPATOLOGY, 2011, 55 (06) :1339-1345

[5]

[Anonymous], MICRORNAS KEY REGULA

[6]

[Anonymous], ASCO M ABSTR

[7] Phase I trial of continuous infusion 5-aza-2′-deoxycytidine [J].

Aparicio, A ;

Eads, CA ;

Leong, LA ;

Laird, PW ;

Newman, EM ;

Synold, TW ;

Baker, SD ;

Zhao, M ;

Weber, JS .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 51 (03) :231-239

[8] A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies [J].

Arkenau, H. -T. ;

Plummer, R. ;

Molife, L. R. ;

Olmos, D. ;

Yap, T. A. ;

Squires, M. ;

Lewis, S. ;

Lock, V. ;

Yule, M. ;

Lyons, J. ;

Calvert, H. ;

Judson, I. .

ANNALS OF ONCOLOGY, 2012, 23 (05) :1307-1313

[9] R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies [J].

Arts, J. ;

Angibaud, P. ;

Marieen, A. ;

Floren, W. ;

Janssens, B. ;

King, P. ;

van Dun, J. ;

Janssen, L. ;

Geerts, T. ;

Tuman, R. W. ;

Johnson, D. L. ;

Andries, L. ;

Jung, M. ;

Janicot, M. ;

van Emelen, K. .

BRITISH JOURNAL OF CANCER, 2007, 97 (10) :1344-1353

[10] Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma [J].

Asangani, Irfan A. ;

Harms, Paul W. ;

Dodson, Lois ;

Pandhi, Mithil ;

Kunju, Lakshmi P. ;

Maher, Christopher A. ;

Fullen, Douglas R. ;

Johnson, Timothy M. ;

Giordano, Thomas J. ;

Palanisamy, Nallasivam ;

Chinnaiyan, Arul M. .

ONCOTARGET, 2012, 3 (09) :1011-1025

← 1 2 3 4 5 6 7 8 9 10 →